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Abstract
To explore novel genetic loci for diabetic nephropathy, we performed genome-wide associa-
tion studies (GWAS) for diabetic nephropathy in Japanese patients with type 2 diabetes. We
analyzed the association of 5,768,242 single nucleotide polymorphisms (SNPs) in Japanese
patients with type 2 diabetes, 2,380 nephropathy cases and 5,234 controls. We further per-
formed GWAS for diabetic nephropathy using independent Japanese patients with type 2
diabetes, 429 cases and 358 controls and the results of these two GWAS were combined
with an inverse variance meta-analysis (stage-1), followed by a de novo genotyping for the
candidate SNP loci (p < 1.0 × 10−4) in an independent case-control study (Stage-2; 1,213
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cases and 1,298 controls). After integrating stage-1 and stage-2 data, we identified one
SNP locus, significantly associated with diabetic nephropathy; rs56094641 in FTO, P = 7.74
× 10−10. We further examined the association of rs56094641 with diabetic nephropathy in
independent Japanese patients with type 2 diabetes (902 cases and 1,221 controls), and
found that the association of this locus with diabetic nephropathy remained significant after
integrating all association data (P = 7.62 × 10−10). We have identified FTO locus as a novel
locus for conferring susceptibility to diabetic nephropathy in Japanese patients with type 2
diabetes.
Introduction
Diabetic nephropathy is a leading cause of end-stage renal disease (ESRD), and its prevalence
is progressively increasing according to the increase of number of patients with diabetes melli-
tus [1,2]. Prolonged persistent hyperglycemia is a principal cause of diabetic microvascular
complications, but it has been shown that only ~30% of all patients with diabetes develop overt
nephropathy, whereas most patients develop diabetic retinopathy 20–30 years after the onset
of diabetes [3]. In addition, familial clustering of diabetic nephropathy has been observed in
both type 1 and type 2 diabetes [4–6], implying that genetic factors are involved in the develop-
ment and/or progression of diabetic nephropathy. Identification of disease susceptibility loci
for many common diseases such as type 2 diabetes, has been achieved by the introduction of
genome-wide association studies (GWAS). Worldwide efforts to identify susceptibility loci for
diabetic nephropathy, however, have not yet met with success so much. Several susceptibility
loci to diabetic nephropathy or its related traits which showed their lowest p-values close to or
with a genome-wide significance level have been unveiled; rs2268388 in ACACB [7],
rs7583877 in AFF3 locus, rs17709344 in RGMA-MCTP2 locus [8], rs4972593 in Sp3-CDCA7
locus [9], rs1801239 in CUBN locus [10], rs161740 in EPO locus [11]. However, the results
have not been conclusive, and thus most susceptibility loci for diabetic nephropathy remain to
be un-identified, suggesting heterogeneity of the disease or contribution of non-genetic fac-
tors, which have not been taken into account, may produce inconsistent results among the
studies.
In this study, to identify novel susceptibility loci to diabetic nephropathy, we performed a
GWAS meta-analysis for diabetic nephropathy using existing Japanese GWAS data for
patients with type 2 diabetes.
Materials and methods
Study subjects
Discovery stage (Stage-1). We selected 7,641 individuals having type 2 diabetes registered
in Biobank Japan, and divided these patients into two groups (stage-1, set-1); 1) 2,380
nephropathy cases, defined as patients with overt albuminuria or under renal replacement
therapy and 2) 5,234 controls with normoalbuminuria and with diabetes duration of 5 years or
longer or with diabetic retinopathy. We also used independent patients with type 2 diabetes
who were extracted from previously reported GWAS data [12], and performed GWAS for dia-
betic nephropathy (stage-1 set 2, cases, n = 429, controls, n = 358). There was no overlap
between set-1 and set-2. Diabetes was diagnosed according to the World Health Organization
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(WHO) criteria [13], and those who were diagnosed as type 1 diabetes, mitochondrial diseases
or maturity-onset diabetes of the young were excluded.
Validation analysis (Stage-2). We examined independent 2,511 patients with Japanese
patients with type 2 diabetes, 1,213 diabetic nephropathy cases and 1,298 controls, from the
BioBank Japan that were not included in the discovery stage.
Clinical characteristics of participants for Stage-1 (set-1, set-2) and Stage-2 are shown in
Table 1. Genomic DNA was extracted from peripheral leukocytes using the standard proce-
dure. All individuals provided written informed consent to participate in this study.
Genotyping, quality control and imputation in the discovery stage
Set-1 individuals in stage 1 were genotyped using the Human Omni Express Exome Bead
Chip. There were 628,670 autosomal SNPs that passed quality control, a call rate� 0.99,
Hardy-Weinberg equilibrium test P� 1 × 10−6 in controls and minor allele frequency (MAF)
� 0.01. Set-2 samples were genotyped using the Illumina Human 610K SNP array, and
504,984 autosomal SNPs passed the quality control described above and used for further analy-
sis. For sample quality control, we evaluated cryptic relatedness for each sample using an iden-
tity-by-state method and removed samples that exhibited second-degree or closer relatedness.
We performed principal component analysis to select individuals belong to the major Japanese
cluster (Hondo cluster, S1 Fig) as reported previously [14], and data for 7,614 individuals
(2,380 diabetic nephropathy cases and 5,234 controls) in set-1 and 787 individuals (429 dia-
betic nephropathy cases and 358 controls) in set-2 were used in subsequent analyses. We per-
formed genotype imputation with MACH and Minimac [15,16] using linkage disequilibrium
data in the 1000 Genomes Project (phased JPT, CHB and Han Chinese South data n = 275,
March 2012) as reference populations. To evaluate the potential effect of population stratifica-
tion, we used a quantile-quantile (qq) plot of the observed P-values.
De novo genotyping
We genotyped 1,213 individuals with diabetic nephropathy and 1,298 controls (Stage-2) regis-
tered as type 2 diabetes in BioBank Japan, who were not included in a discovery stage using a
multiplex PCR-invader assay [17] for SNPs with p values < 10−4 in the meta-analysis. We also
genotyped additional 2,123 Japanese patients with type 2 diabetes (902 diabetic nephropathy
cases and 1,221 controls), who visited out-patient clinics of Tokai university hospital, Shiga
university of medical science hospital, Juntendo university hospital, Kawasaki medical school
hospital, Tokyo women’s medical university hospital, Iwate Medical University, Toride Kyodo
Table 1. Clinical characteristics of participants.
Stage1 Stage2
Set1 Set2
case control case control case control
n 2,380 5,234 429 358 1,213 1,298
M/F 1,611/769 3,162/2,072 304/125 226/131�� 833/380 759/539
Men% 67.6 60.4 70.9 63.1 68.6 58.5
age 65.9 ± 10.5 66.3 ± 9.6 67.2 ± 10.0 66.9 ± 9.2 63.9 ± 11.0 63.9 ± 10.5
BMI 23.9 ± 4.0� 23.6 ± 3.6 23.5 ± 4.0 23.8 ± 3.8 24.1 ± 3.9 23.6 ± 3.8
Diabetes duration 13.1 ± 9.8� 14.4 ± 8.5 13.4 ± 10.2 13.2 ± 10.0 12.0 ± 9.5 10.5 ± 8.8
� P < 0.01 vs. control
�� information of sex for one participant is not available
https://doi.org/10.1371/journal.pone.0208654.t001
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Hospital, Kawai Clinic, Osaka City General Hospital, Chiba Tokusyukai Hospital or Osaka
Rosai Hospital.
Genotyping success rates < 95% or concordance rates < 99.9% were excluded from the
analyses.
Statistical analysis
The association between each SNP and diabetic nephropathy was assessed using the logistic
regression test with an additive model with or without adjusting for age, sex, and log-trans-
formed body mass index (BMI) using Mach2dat. We combined data from the each GWAS,
validation and replication studies using METAL [18] as an inverse variance method. Heteroge-
neity in effect sizes among the studies was evaluated with a Cochran’s Q test. Regional associa-
tion plots were generated using LocusZoom [19].
Ethics approval
The protocol of this study conformed to the provisions of the Declaration of Helsinki and was
approved by the ethical committees at the RIKEN Yokohama Institute, Tokai university hospi-
tal, Shiga university of medical science, Juntendo university, Kawasaki medical school, Tokyo
women’s medical university and Iwate Medical University, and the institutional review boards
at Toride Kyodo Hospital, Osaka City General Hospital, Chiba Tokusyukai Hospital and
Osaka Rosai Hospital.
Results
A meta-analysis of GWAS for diabetic nephropathy in the Japanese
patients with type 2 diabetes
We obtained genotype data for 7,521,074 SNPs by imputation, and among them, 5,768,242
SNPs those passed quality control (r2 > 0.7) in both studies (Stage-1 set-1 and set-2) were eval-
uated in this meta-analysis (Fig 1).
There was no genomic inflation in the qq plots in the both studies (S2 Fig). We selected 77
loci associated with diabetic nephropathy in the meta-analysis (P< 1 × 10−4, S1 Table), and the
associations of the lead SNPs from the 77 loci with DN were examined in an independent case-
control study (Stage-2, 1,213 cases and 1,298 controls). In stage-2 analyses, we successfully
obtained the genotype data for 65 loci by the multiplex-PCR invader assay. After combining all
association data (Stage-1 set-1, set-2 and Stage-2) using the inverse-variance fixed-effects meta-
analysis, we found that one SNP locus, rs56094641 in FTO at chromosome (Chr) 16, 16q12.2,
showed a genome-wide significant association with diabetic nephropathy (P = 7.74 × 10−10,
odds ratio (OR) = 1.23, 95% confidence interval (CI) 1.15−1.31, Table 2 and S2 Table). The
association of the FTO locus with overt nephropathy was not affected by an adjustment for age,
sex and BMI (rs9936385, r2 = 1 with rs56094641, S3 Table). We additionally identified sugges-
tive evidence for the associations of six SNP loci with diabetic nephropathy (5.0 × 10−8 <
P< 5.0 × 10−7, Table 2 and S2 Table): rs895157 in PRCD (17q25.1, P = 7.70 × 10−8, OR = 1.28,
95% CI 1.17−1.41), rs10144968 near RAD51B (14q24.1–24.2, P = 1.22 × 10−7, OR = 1.35, 95%
CI 1.21−1.51), rs13306536 in LRP8 (1p32.3, P = 2.70 × 10−7, OR = 1.33, 95% CI 1.19−1.48),
rs7544082 near TRABD2B (1p33, P = 3.08 × 10−7, OR = 1.17, 95% CI 1.10−1.24), rs11101179 in
CHAT (10q11.2–21.1, P = 3.85 × 10−7, OR = 1.19, 95% CI 1.11−1.28), rs710375 near CCNH
(5q14-15, P = 3.96 × 10−7, OR = 1.21, 95% CI 1.12−1.30). Regional plots for these 7 loci are
shown in S3 Fig.
FTO and susceptibility to diabetic nephropathy
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Replication study
We examined the association of rs56094641 in FTO with overt nephropathy in 2,123 Japanese
patients with type 2 diabetes (cases n = 902, controls n = 1,221). As shown in Table 3,
rs56094641 in FTO showed the same direction of effect with the original finding in the discov-
ery stage. The association of rs56094641 in FTO with overt nephropathy was still genome-wide
significant level after integration of all association data (P = 7.62 × 10−10, OR = 1.21, 95% CI
1.14−1.29, Table 3) though the association was not statistically significant in the replication
study alone (P = 0.258, OR = 1.11, 95% CI 0.93−1.32, Table 3).
By in silico replication using SUMMIT consortium data for type 2 diabetes, the association
of FTO variants with diabetic nephropathy was not replicated in European patients with type 2
diabetes (Table 3).
Evaluation of previously reported loci
We reflected our results (meta-analysis of Stage-1 set-1 and set-2) on previously- reported sus-
ceptibility loci to overt nephropathy. There was no overlap between the above seven SNP loci
Fig 1. Outline of this study. � r2 > 0.7 in both studies, SNP; single nucleotide polymorphism, MAF; minor allele frequency, HWE P; Hardy-Weinberg Equilibrium test
P, RSQ, r square.
https://doi.org/10.1371/journal.pone.0208654.g001
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and 21 loci from previously-reported GWAS for susceptibility to overt nephropathy (S4
Table). None of the SNPs in the original reports showed significant association with overt
nephropathy in the discovery stage (P> 2.38 x 10−3 = 0.05/21). Regional lead SNPs within the
ELMO1, RGMA-MCTP2, ERBB4 and SP3-CDCA7 in the discovery stage attained the threshold
of the correction of multiple testing error.
Discussion
From a result of GWAS meta-analysis for diabetic nephropathy followed by validation studies
in Japanese patients with type 2 diabetes, which comprising in 4,022 cases and 6,890 controls,
we identified significant association between rs56094641 in FTO and susceptibility to diabetic
nephropathy in Japanese patients with type 2 diabetes.
FTO locus has been repeatedly reported to be associated with obesity and/or adiposity [20],
and, in this study, we have shown that the risk allele for obesity was significantly associated
with susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes.
Smemo et al. mentioned that obesity-associated noncoding sequences within FTO are func-
tionally connected, at megabase distances, with the homeobox gene IRX3 [21]. IRX3 is a




Alleles study RAF OR (95%CI) P Phet
rs56094641 G/A Stage-1, set-1 0.247/0.211 1.22 (1.13–1.32) 1.19 × 10−6
FTO Stage-1, set-2 0.236/0.207 1.19 (0.93–1.52) 0.164
Ch16 Stage-2 0.252/0.209 1.27 (1.11–1.46) 3.76 × 10−4
Combined 1.23 (1.15–1.31) 7.74 × 10−10 0.85
rs895157 C/A Stage-1, set-1 0.130/0.108 1.28 (1.14–1.43) 2.85 × 10−5
PRCD Stage-1, set-2 0.126/0.113 1.14 (0.83–1.58) 0.422
Ch17 Stage-2 0.140/0.109 1.35 (1.13–1.60) 7.02 × 10−4
Combined 1.28 (1.17–1.41) 7.70 × 10−8 0.67
rs10144968 G/T Stage-1, set-1 0.078/0.062 1.27 (1.11–1.46) 3.75 × 10−4
RAD51B Stage-1, set-2 0.083/0.060 1.41 (0.95–2.10) 8.48 × 10−2
Stage-2 0.078/0.051 1.58 (1.25–1.99) 1.15 × 10−4
Combined 1.35 (1.21–1.51) 1.22 × 10−7 0.28
rs13306536 T/C Stage-1, set-1 0.089/0.068 1.27 (1.11–1.46) 3.75 × 10−4
LRP8 Stage-1, set-2 0.068/0.075 0.87 (0.58–1.30) 0.496
Ch1 Stage-2 0.076/0.058 1.35 (1.08–1.69) 1.15 × 10−4
Combined 1.33 (1.19–1.48) 2.70 × 10−7 0.1
rs7544082 A/C Stage-1, set-1 0.525/0.492 1.18 (1.09–1.27) 3.22 × 10−5
TRABD2B Stage-1, set-2 0.550/0.514 1.15 (0.77–1.72) 0.164
Ch1 Stage-2 0.552/0.514 1.16 (1.04–1.31) 8.70 × 10−3
Combined 1.17 (1.10–1.24) 3.08 × 10−7 0.97
rs11101179 C/T Stage-1, set-1 0.231/0.197 1.22 (1.12–1.33) 2.23 × 10−6
CHAT Stage-1, set-2 0.205/0.205 1.00 (0.77–1.31) 0.977
Ch10 Stage-2 0.226/0.198 1.17 (1.02–1.34) 2.10 × 10−2
Combined 1.19 (1.11–1.28) 3.85 × 10−7 0.37
rs710375 C/T Stage-1, set-1 0.201/0.169 1.24 (1.14–1.36) 2.23 × 10−6
CCNH-TMEM161B Stage-1, set-2 0.197/0.154 1.38 (1.04–1.77) 0.977
Ch5 Stage-2 0.187/0.176 1.08 (0.93–1.24) 2.10 × 10−2
Combined 1.21 (1.12–1.30) 3.96 × 10−7 0.16
https://doi.org/10.1371/journal.pone.0208654.t002
FTO and susceptibility to diabetic nephropathy
PLOS ONE | https://doi.org/10.1371/journal.pone.0208654 December 19, 2018 6 / 13
member of the Iroquois homeobox gene family and plays a role in an early step of neural
development [22]. Members of this family including IRX3 and IRX5 appear to play multiple
roles during pattern formation of vertebrate embryos [23]. However, there is no evidence
showing functional link between IRX3/IRX5 and diabetic nephropathy.
Obesity has been recognized as an important risk factor for chronic kidney disease (CKD)
[24,25]. The incidence of obesity has actualized an increase the number of patients with obe-
sity-related glomerulopathy and proteinuria [26]. Furthermore, obesity has been reported to
be an independent risk factor for ESRD by a large historical cohort study of 177,570 adults
after adjustment for multiple epidemiologic and clinical conditions including diabetes [27]
Moreover, a FTO variant, rs17817449, which are in absolute linkage disequilibrium to
rs56094641, was shown to be associated with ESRD [28], suggesting FTO variants confer sus-
ceptibility to CKD/ESRD through the mechanisms mediated by obesity/adipocity.
In European patients with type 1 or type 2 diabetes, a genetic risk score constructed from
confirmed obesity related SNP loci was associated with diabetic nephropathy [29–31],
although FTO variant alone did not have significant effect on any of renal phenotype.
Table 3. Replication studies for 7 loci associated with diabetic nephropathy.
SNP ID
gene
Alleles Ethnicity RAF OR (95%CI) P Phet
rs56094641 G/A Japanese Discovery 1.23 (1.15–1.31) 7.74 × 10−10
FTO Replication 1.11 (0.93–1.32) 0.258
Combined 1.21 (1.14–1.29) 7.62 × 10−10 0.67
Europeans 1.06 (1.19–0.95) 0.300
rs895157 C/A Japanese Discovery 1.28 (1.17–1.41) 7.70 × 10−8
PRCD Replication 0.96 (0.77–1.21) 0.748
Combined 1.23 (1.13–1.34) 1.15 × 10−6 0.11
Europeans 0.92 (0.80–1.06) 0.195
rs10144968 G/T Japanese Discovery 1.35 (1.21–1.51) 1.22 × 10−7
RAD51B Replication 1.04 (0.76–1.41) 0.808
Combined 1.31 (1.18–1.45) 4.23 × 10−7 0.17
Europeans 0.91 (0.80–1.03) 0.289
rs13306536 T/C Japanese Discovery 1.33 (1.19–1.48) 2.70 × 10−7
LRP8 Replication 0.98 (0.72–1.34) 0.914
Combined 1.30 (1.16–1.42) 1.38 × 10−6 0.05
Europeans N/A N/A
rs7544082 A/C Japanese Discovery 1.17 (1.10–1.24) 3.08 × 10−7
TRABD2B Replication 0.99 (0.86–1.15) 0.946
Combined 1.16 (1.04–1.31) 2.58 × 10−6 0.24
Europeans N/A N/A
rs11101179 C/T Japanese Discovery 1.19 (1.11–1.28) 3.85 × 10−7
CHAT Replication 0.92 (0.77–1.10) 0.365
Combined 1.15 (1.08–1.23) 9.36 × 10−6 0.03
Europeans N/A N/A
rs710375 C/T Japanese Discovery 1.21 (1.12–1.30) 3.96 × 10−7
CCNH Replication 0.85 (0.70–1.03) 9.86 × 10−2
Combined 1.16 (1.08–1.24) 3.02 × 10−5 0.002
Europeans 1.12 (0.999–1.12) 3.58 × 10−2
N/A, data is not available
https://doi.org/10.1371/journal.pone.0208654.t003
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Therefore, our report is the first to show a robust association of FTO variant with diabetic
nephropathy. In addition, adjustment for BMI did not influence the association of the SNP
with diabetic nephropathy in this study, suggesting that the SNP gets involved in susceptibility
to diabetic nephropathy through the mechanism other than increasing BMI. Values of BMI
used in this study, however, were obtained after making diagnosis of type 2 diabetes and some
therapeutic interventions might affect the BMI values used in this study. Therefore, we might
underestimate the effects of BMI on susceptibility to diabetic nephropathy.
We also obtained six SNP loci, which have shown borderline associations with overt
nephropathy at the discovery stage (Table 1: 5 × 10−8 < combined P� 5 × 10−7), but all candi-
date SNPs did not show significant effects in the replication stage in an independent Japanese
case-control study (Table 3). In this study, we could not replicate almost all of variants identi-
fied by meta-analysis of stage 1 and stage 2 in the additional dataset with a comparable sample
size with stage 2 GWAS. Although genome-wide SNPs data are not available for individuals in
the replication stage, all samples for the replication stage were collected in the Japan main-
island, and it has been shown individuals living in Japan main-island are genetically homoge-
neous [14]; therefore, we think there is no evidence for population heterogeneity between the
discovery stage and the replication stage.
We further performed a GWAS meta-analysis for diabetic nephropathy including patients
with microalbuminuria as cases, and found that rs56094641 in FTO was significantly associ-
ated with diabetic nephropathy also in this analysis (P = 2.40 × 10−9, OR = 1.18, 95% CI 1.15
−1.31, S5 and S6 Tables). However, the association was not stronger than that in the analysis
using overt nephropathy as cases, suggesting the FTO variant was associated with advanced
stages of diabetic nephropathy.
Our study has some limitations. Firstly, the detail clinical information, i.e. blood pressure,
Hemoglobin A1c, lipid profiles, prescription of antihypertensive treatments, was not available
in many participants in Stage-1 samples. It means that we cannot exclude the possibility that
the association of the SNP with diabetic nephropathy is mediated by some risk factors except
age, sex and BMI. Second, by in silico replication using SUMMIT consortium data for type 2
diabetes, the association of FTO variants with diabetic nephropathy was not replicated in
European patients with type 2 diabetes (Table 3, S7 Table), and the association of FTO variants
with diabetic nephropathy showed a genome-wide significant association only in a joint analy-
sis for the discovery stage; therefore, these observations may not be in line with standards for
GWA studies; further study, such as a large-scaled longitudinal study, is required to elucidate
the association of FTO locus with diabetic nephropathy.
Conclusions
We performed GWAS for diabetic nephropathy in Japanese patients with type 2 diabetes. One
SNP locus, FTO locus, showed a significant association with susceptibility to diabetic nephrop-
athy, and the association attained a genome-wide significant level. Further studies are required
to confirm the association of this locus with diabetic nephropathy.
Supporting information
S1 Fig. Results of principal component analysis in stage-1 and stage-2.
(PDF)
S2 Fig. Quantile-quantile plot. A: Stage-1, set-1, B: Stage-1, set-2.
(PDF)
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S3 Fig. Regional plot of each candidate locus. Results of stage-1 GWAS meta-analysis are
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